XML 14 R4.htm IDEA: XBRL DOCUMENT v3.21.2
Consolidated Statements of Income (Loss) - USD ($)
shares in Millions, $ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Net revenues $ 3,887 $ 3,978 $ 11,778 $ 12,206
Cost of sales 2,093 2,126 6,234 6,528
Gross profit 1,794 1,852 5,544 5,678
Research and development expenses 222 258 723 704
Selling and marketing expenses 597 605 1,798 1,815
General and administrative expenses 291 279 822 846
Intangible assets impairments 21 509 295 1,278
Goodwill impairment 0 4,628 0 4,628
Other assets impairments, restructuring and other items 62 (98) 227 404
Legal settlements and loss contingencies 3 21 113 10
Other income (25) (8) (73) (30)
Operating income (loss) 623 (4,342) 1,638 (3,978)
Financial expenses, net 241 117 805 565
Income (loss) before income taxes 382 (4,459) 833 (4,543)
Income taxes (benefit) 76 16 235 (147)
Share in (profits) losses of associated companies, net 5 (136) (9) (135)
Net income (loss) 302 (4,340) 608 (4,261)
Net income (loss) attributable to non-controlling interests 11 10 32 (121)
Net income (loss) attributable to Teva $ 292 $ (4,349) $ 576 $ (4,140)
Earnings (loss) per share attributable to ordinary shareholders:        
Basic $ 0.26 $ (3.97) $ 0.52 $ (3.78)
Diluted $ 0.26 $ (3.97) $ 0.52 $ (3.78)
Weighted average number of shares (in millions):        
Basic 1,103 1,096 1,102 1,095
Diluted 1,109 1,096 1,109 1,095